Tag: HIV Prevention

  • Local Lenacapavir Production: Aspen Exits, Eyes Alimatravir

    Aspen is giving up on local lenacapavir production because demand isn’t guaranteed. Instead, the company is supporting Merck’s alimatravir pill as a means of preventing HIV. Aspen Pharmacare has walked away from government plans to produce lenacapavir locally. This is the clearest sign yet that South Africa’s bid to make its own HIV prevention injection faces stiff commercial headwinds. Instead,…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Lenacapavir HIV prevention faces SA supply constraints

    Lenacapavir HIV prevention could significantly shorten the time South Africa needs to bring HIV transmission under control. However, modelling suggests the country would need millions of people to receive the long-acting injection each year to realise its full potential. Clinical trials found that lenacapavir provided almost complete protection against HIV infection. The injectable prevention option could also address a persistent…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • PEPFAR Funding Cuts Deepen Global HIV Crisis

    An inaccurate map of Africa presented at the 26th International AIDS Conference in Rio de Janeiro drew criticism. US officials incorrectly placed Mozambique in the Horn of Africa and moved Ivory Coast from West to East Africa. The mistakes damaged the goodwill built by the Trump administration’s decision to attend the conference, and officials also addressed questions about changes to…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Lenacapavir Production in South Africa Moves Closer

    Three South African pharmaceutical manufacturers have reached the shortlist to potentially produce Gilead Sciences’ HIV-prevention injection, lenacapavir. Deputy Health Minister Joe Phaala confirmed the development at the 26th International Aids Conference in Rio de Janeiro. The South African National Aids Council evaluated submissions received through a call for expressions of interest. It then selected three possible manufacturers. Phaala declined to…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Older Adults With HIV Set To Double By 2040

    The number of older adults with HIV will rise sharply over the next 15 years, testing health systems never built for their complex needs. A new report in The Lancet projects that the global number of people aged 50 and older living with HIV will almost double between 2025 and 2040. The total is expected to climb from 11.5 million…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Global HIV Funding Cuts Put AIDS Progress At Risk

    Global HIV funding cuts pushed international financing for the epidemic to its lowest level in almost two decades in 2025. Funding from several donor countries fell by 18% between 2024 and 2025, according to a new UNAIDS report. The total declined by more than $1.5bn to $7.3bn. The contraction comes at a critical point in the global response to HIV.…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Aspen HIV Prevention Pill Deal Expands African Access

    Aspen Pharmacare will become a major African supplier of Merck’s experimental monthly HIV prevention pill, alimatravir. The agreement depends on the medicine successfully completing clinical trials and receiving regulatory approval. Merck granted voluntary licenses to seven generic drug manufacturers, including the South African company, to produce and distribute lower-cost versions of the medicine. The drug also goes by its development…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Lenacapavir HIV Prevention Could Transform South Africa

    Over the past four decades, antiretroviral therapy has transformed HIV care. A diagnosis that was once frequently fatal can now be managed as a chronic condition. Treatment has extended life expectancy and improved quality of life. It has also enabled millions of people living with HIV to remain healthy and productive. Preventing new infections remains a major challenge. South Africa…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Global HIV Treatment Gap Leaves 8.8 Million Behind

    Nearly nine million people living with HIV are not receiving treatment, despite major progress in expanding access to antiretroviral medicines. UNAIDS estimates that 40.9 million people were living with HIV in 2025. Of these, 32.1 million were accessing antiretroviral therapy. This means about 8.8 million people remained without treatment. Around 78% of people living with HIV had access to treatment.…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Lenacapavir PrEP Rollout Brings Hope Amid Service Cuts

    South Africa has launched lenacapavir, a new injectable form of pre-exposure prophylaxis, or PrEP. The injection provides six months of protection against HIV infection. It is given twice a year. Health experts say the Lenacapavir PrEP Rollout could be a major step forward for HIV prevention. It offers an alternative to oral PrEP, which requires people to take tablets regularly.…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Lenacapavir HIV Prevention Injection: SA Rollout Faces Heat

    South Africa’s long-acting HIV prevention programme has entered a new phase. President Cyril Ramaphosa and Health Minister Aaron Motsoaledi led an official rollout event in Secunda, Mpumalanga, on 5 June 2026. The twice-yearly injection of lenacapavir prevents HIV infection when used as prescribed. Health officials position the product as a major addition to the country’s prevention toolkit. This is alongside…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Lenacapavir Manufacturing In SA: Strengthening Production

    A new wave of “America First” industrial policy is reshaping global supply chains. Medicines and vaccines are increasingly treated as strategic assets, not just commercial products. That shift matters for South Africa, which still relies heavily on imports for essential health technologies, making discussions around Lenacapavir Manufacturing in SA increasingly important. The COVID-19 pandemic exposed how quickly supply lines can…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in